Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
399
resultados
Última actualización
10/09/2026 [09:08:00]
Resumen de: WO2025080149A1
A method for assaying the presence of two genetic polymorphisms whose occurrence significantly modifies the course of COVID-19 disease is disclosed. The genetic polymorphisms, namely rs143334143 locus and at the rs74956615. This method represents a new tool in the public health protection against COVID-19 disease.
Resumen de: US20260256905A1
0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.
Resumen de: US20260259197A1
The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.
Resumen de: US20260259196A1
Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) from a subject that has been administered a an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus contains antibodies that inhibit influenza virus hemagglutinin (HA) glycoprotein hemagglutination activity, antibodies that neutralize SARS-COV-2 virus, antibodies that bind SARS-COV-2 spike protein, and/or antibodies that neutralize seasonal influenza virus. The methods include assaying a biological sample, where the biological sample is from a subject that has been administered an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus, and is not significantly affected by interference of analyte detection between the methods.
Resumen de: WO2026182475A1
The present invention relates to a recombinant adenovirus comprising a SARS-CoV-2-derived receptor-binding domain and an antibody Fc region, and a use thereof, and provides: a polynucleotide comprising a SARS-CoV-2 spike-derived receptor-binding domain and an antibody Fc region; a recombinant adenovirus comprising the polynucleotide; and a vaccine composition for preventing SARS-COV-2 infection, comprising the recombinant adenovirus as an active ingredient.
Resumen de: US20260256871A1
0000 The application is directed to methods for treatment or prevention of SARS-CoV-2 infection in a subject in need thereof, the composition comprising an organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically acceptable salt thereof, and methods of using the same.
Resumen de: EP4799624A2
Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications associated with RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising Pipendoxifene or analogues thereof (e.g., a compound of Formula (I), Formula (II), or Formula (III)) to a patient in need. One or more additional therapeutic agents can also be administered to the patient in the disclosed methods.
Resumen de: WO2025090605A1
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Resumen de: MA70856A1
Cette invention est relative à de nouveaux composés à base de lacide éthacrynique couplé avec des acides aminés modifiés comme lillustre la formule (I). Ces composés sont conçus pour le traitement du SARS-CoV-2, des pathologies liées à la COVID-19, ainsi que des maladies associées aux -coronavirus. Cette invention porte également sur leur application in vitro pour étudier l'inhibition de la réplication du SARS CoV2. De plus, cette invention inclut des compositions pharmaceutiques comprenant, comme principe actif, au moins un composé de la formule (I).
Resumen de: WO2026178292A1
Microneedle patches or microneedle array patches (MAPs) offer a convenient method to intradermally deliver drugs and vaccines. Embodiments include MAPs that overcome the limitations of conventional MAPs. In aspects, the MAPs include (a) a base, (b) an adhesive region and (c) a plurality of needles on a surface of the base. The needles can comprise a medicament (e.g., a therapeutic or vaccine). In aspects, the medicament is a circular RNA vaccine that elicits an immune response against SARSCoV-2.
Resumen de: WO2026174523A1
The present invention relates to the field of cancer immunotherapy technology, and specifically, to a recombinant HPV16 E6E7 adenovirus, a vaccine thereof, a method for preparing same, and use thereof. The present invention provides a recombinant HPV16 E6E7 adenovirus, comprising an HPV16 E6E7 antigen sequence and SARS-CoV-2 virus HR1 and HR2 region sequences. The recombinant HPV16 E6E7 adenovirus vaccine prepared by using the adenovirus, when used either alone or in combination with other anti-tumor drugs, can significantly inhibit the growth of tumors in cervical cancer and head and neck squamous cell carcinoma, and induce a significant cellular immune response in mice.
Resumen de: US20260250326A1
0000 The present invention relates to a method for producing immunogenic compositions, such as vaccines, by identifying amino acid sequence of antigenic patches (Ag-Patches) from at least one proteome of a pathogen, derived from overlapping epitope clusters. In particular, the invention relates to the design of Multi-Patch Vaccines against viral, such as SARS-CoV-2, bacterial, fungi, parasite, pathogenic and non-pathogenic targets.
Resumen de: US20260251661A1
A method for testing a diseased state of vasculitis and a method for testing an exacerbation risk of COVID-19, the method including: detecting or quantifying, in a blood sample collected from a subject, (1) a No. 1 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 23 to 25 kDa, and/or (2) a No. 2 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 16 to 20 kDa.
Resumen de: WO2026175420A1
Provided are a fusion protein of an ultra-stable intracellular antibody targeting PDIA3 and the use thereof. The fusion protein comprises an antigen-binding peptide targeting PDIA3 and an intracellular stabilizing peptide. The antigen-binding peptide comprises a heavy chain variable region and a light chain variable region. By means of optimally designed intracellular stabilizing peptide and signal peptide sequences, the antibody can stably exist in cells and specifically localize to the endoplasmic reticulum. The fusion protein can effectively target and bind to the PDIA3 protein, significantly inhibit the expression levels of S proteins from human coronaviruses and capsid proteins from various non-enveloped viruses in cells, and regulate endoplasmic reticulum stress via protein-protein interactions on the ER of host cells, thereby promoting the degradation of the viral proteins and further effectively reducing the infectivity of the viruses.
Resumen de: US20260250363A1
0000 Provided herein are antibodies or antigen binding fragments thereof having a binding specificity for SARS-CoV-2 spike protein, and bispecific antibodies comprising a first and a second antigen binding region that bind to SARS-CoV-2 spike protein. Also provided herein are pharmaceutical compositions comprising the antibodies, antigen binding fragments thereof, or bispecific antibodies.
Resumen de: EP4796155A2
Provided herein are devices and methods that relate to ventilation and respiration. In one embodiment, a ventilator device comprising a fluidic amplifier with one or more coaxially aligned components, where there are no internal moving components. In another embodiment, a device and related methods for treating a patient who needs ventilation such as after infection by the coronavirus Covid-19.
Resumen de: EP4266057A1
The invention relates to an in vitro method for the detection of inflammation caused by an acute COVID-19 infection, long COVID and/or PIMS, wherein the level of kynurenine in a body fluid is determined and wherein the value of kynurenine measured in the patient to be diagnosed is compared with the average value obtained from a comparable cohort of persons who do not suffer from said diseases, whereby the value of kynurenine in patients is increased.
Resumen de: US20260240794A1
The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.
Resumen de: WO2026172365A1
This study presents the synthesis of novel Benzodiazocine analogues and their potential as potent antiviral agents. Benzodiazocines, featuring an eight-membered fused bicyclic core, adhere to Lipinski's rule of five, ensuring drug-like properties. Structural modifications via Structure-Activity Relationship (SAR) enhanced their antiviral efficacy. In vitro assays, including cytotoxicity analysis and RT-qPCR-based studies, evaluated activity against SARS- CoV-2. Several analogues demonstrated promising antiviral potential, contributing to the ongoing pursuit of effective therapeutics against viral infections.
Resumen de: US20260242880A1
Provided are methods for co-extraction of DNA or RNA from two or more pathogens (such as Mycobacterium tuberculosis (Mtb) and SARS-CoV-2 (SC2)) in a sample. Also provided are assays for identifying a pathogen (such as Tuberculosis (TB)) directly from a sample.
Resumen de: US20260242881A1
0000 Methods are provided for determining whether a subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, influenza A, human immunodeficiency virus type 1 (HIV-1), methicillin-susceptible Staphylococcus aureus (MSSA), or methicillin-resistant Staphylococcus aureus (MRSA), or has been exposed to an organophosphate (OP). Such methods include determining the measuring methylation status of numerous differentially methylated regions (DMRs) in the genomic DNA of particular PBMCs, such as those provided in Table 1, and in some examples also determining an amount of accessible chromatin in the isolated immune cells. Also provided are nucleic acid probes, arrays, solid supports (such a chip or nanosphere) and kits that can be used with such methods.
Resumen de: US20260240922A1
0000 The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, comprising a lactic acid bacterium. The chemosensory disorder can be a chemosensory disorder that occurs after SARS-CoV-2 viral infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect against a chemosensory disorder, and a pharmaceutical product or a food product that is safe for mammals including humans can be provided.
Resumen de: US20260242415A1
0000 The present invention relates to novel cyclic peptides. The peptides bind viral proteins, particularly a conserved site on the SARS-CoV-2 spike protein, and therefore the peptides can be useful for neutralizing SARS-CoV-2 variants. Accordingly, the invention also relates to medical use of the peptides.
Resumen de: US20260242763A1
0000 A fully human ACE2-Fc fusion protein, a pharmaceutical composition, preparation and kit containing same, and a nasal spray containing the fusion protein. Also provided is a use of the fusion protein for broad-spectrum prevention of coronavirus infections, such as infections with coronavirus SARS-CoV-2 and known and unknown variants thereof, including but not limited to original Hu-1, alpha, beta, gamma, delta, mu, omicron, JN.1, and/or other future strains. Also provided are a method for producing the fusion protein, and a method for using the fusion protein to prevent and/or treat infections with coronavirus SARS-CoV-2 and known and unknown variant strains thereof. Further provided is a use of the fusion protein and the pharmaceutical composition and preparation containing same for preventing the spread of coronavirus SARS-CoV-2 and known and unknown variant strains in infected subjects.
Nº publicación: AU2026210797A1 20/08/2026
Solicitante:
SKYDD BIOTECHNOLOGY PTY LTD
SKYDD Biotechnology Pty Ltd.
Resumen de: AU2026210797A1
WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies 5 N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, and the designing of treatment targets and designing of vaccine targets. In the above amino acid sequence group, it is found that P272 in only one aa261-275 sequence of an S protein is a residue with a low-frequency mutation, and the remaining 19 sequences are 10 conservative amino acid sequences, do not contain the currently discovered virus mutation sites, and are highly conservative, which can effectively cope with the unfavorable situation of high-frequency mutation of SARS-CoV-2 at present. WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid 5 sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, a
BOPI
Sede Electrónica
